CAH Cardinal Health, Inc. Common Stock
Cardinal Health, Inc. Common Stock 정보 위키백과 회사 개요
Cardinal Health Technologies, LLC doing business as Cardinal Health, is an American multinational health care services company, and the 15th highest revenue generating company in the United States. Headquartered in Dublin, Ohio, the company specializes in the distribution of pharmaceuticals and medical products, serving more than 100,000 locations. The company also manufactures medical and surgical product, including gloves, surgical apparel, and fluid management products. In addition, it operates one of the largest networks of radiopharmacies in the U.S. Cardinal Health provides medical products to over 75 percent of hospitals in the United States.
더 보기
Cardinal Health Technologies, LLC doing business as Cardinal Health, is an American multinational health care services company, and the 15th highest revenue generating company in the United States. Headquartered in Dublin, Ohio, the company specializes in the distribution of pharmaceuticals and medical products, serving more than 100,000 locations. The company also manufactures medical and surgical product, including gloves, surgical apparel, and fluid management products. In addition, it operates one of the largest networks of radiopharmacies in the U.S. Cardinal Health provides medical products to over 75 percent of hospitals in the United States.
History
Founded in 1971 as Cardinal Foods by Robert D. Walter, the company was initially a food wholesaler. After acquiring the Bailey Drug Company in 1979, it began whole selling drugs. The company went public on the NASDAQ stock exchange in 1983.
In 1988, Walter sold Cardinal Health's food operations to Roundy's. From 1991 to 1996, the company's sales grew from $1.2 billion to $8.9 billion. The company changed its name to Cardinal Health in 1994, and became the third-largest pharmaceutical wholesaler in the United States.
2000–2019
R. Kerry Clark, a former executive and vice chairman at Procter & Gamble, was appointed president and CEO in April 2006, with Robert D. Walter retaining Chairmanship of the board. In September 2008, the company announced Clark and Walter would retire and George S. Barrett would become the chairman and CEO.
In 2009, Cardinal Health completed the spin-off of its clinical and medical products businesses into an independent medical technology company called CareFusion with David Schlotterbeck as CEO. Cardinal Health is now traded on the NYSE under symbol CAH.
In December 2013, it was announced that Cardinal Health would partner with CVS Caremark to form a generic drug sourcing operation in the United States. The venture was named Red Oak Sourcing and began operations in July 2014.
Between 2014 and 2016, Cardinal, alongside McKesson Corporation, and AmerisourceBergen, spent $13 million lobbying Congress to pass Congressman Tom Marino's "Ensuring Patient Access and Effective Drug Enforcement Act". The bill, which increases the burden of proof enforcers need to show against drug distributors, was signed into law by President Barack Obama in April 2016.
In January 2018, Michael Kaufmann assumed the role of CEO after serving as CFO of the company.
Opioid lawsuits
In 2019, Cardinal was one of several drug distributors named in lawsuits related to the opioid crisis in the US. In July 2021, Cardinal Health and other pharmaceutical companies agreed to participate in a $26 billion settlement. Cardinal will pay $6.4 billion over 18 years.
In May 2020, Oklahoma Attorney General Mike Hunter sued Cardinal Health in Bryan County District Court, Oklahoma. The lawsuit alleged that the company's actions helped fuel Oklahoma's opioid crisis. The suit was filed along with lawsuits against AmerisourceBergen and McKesson, and the three lawsuits allege that the three companies provided "enough opioids to Bryan County that every adult resident there could have had 144 hydrocodone tablets."
2020–present
As of August 2021, it is ranked 14 on the Fortune 500 list with FY2020 annual revenue of $152.9 billion. The firm employs 57,000 people worldwide.
Acquisitions
In 1995, Medicine Shoppe International, the country's largest franchiser of retail pharmacies, was acquired. The merger represented the first non-distribution acquisition by Cardinal Health.
In 1996, Cardinal Health acquired Pyxis Corporation, a company that developed automated pill dispensers for hospitals, for $867 million.
In 1997, Cardinal Health planned to purchase Bergen Brunswig Corp., to which McKesson Corporation responded with a bid to purchase Amerisource. Instead, Amerisource and Bergen merged into AmerisourceBergen. Later that year, Cardinal Health completed the acquisition of Owen Healthcare, the second-largest provider of pharmacy management services in the U.S. at the time.
In 1999, the firm acquired the Chicago-based medical products manufacturer and distributor, Allegiance Healthcare (formerly a division of Baxter Healthcare). In 2001, the company acquired Bindley Western Industries, a wholesale distributor of pharmaceuticals based in Indianapolis.
In April 2006, Cardinal Health purchased Niagara Falls-based ParMed Pharmaceuticals for $40.1 million. In June 2007, the firm announced the completion of a tender offer for VIASYS Healthcare.
In June 2010, Cardinal Health announced plans to purchase Healthcare Solutions Holding, a specialty pharmaceutical services company, for $517 million. In December 2010, the company acquired Kinray, an independent pharmaceutical wholesaler, increasing Cardinal Health's presence in the independent pharmacy market by 40 percent. From 2010 to 2014, Cardinal Health acquired 18 companies including Yong Yu, a Chinese drug distributor. Cardinal sold Yong Yu in 2017 to Shanghai Pharmaceuticals Holding Co. Ltd. for $1.2 billion.
On March 18, 2013, Cardinal Health acquired the Twinsburg, Ohio-based privately held medical supply distributor AssuraMed, and with it its subsidiaries including Edgepark Medical Supplies, for $2.7 billion. AssuraMed was backed by private equity firms Clayton, Dubilier & Rice and Goldman Sachs Alternatives.
In July 2014, Cardinal Health and CVS formed Red Oak Sourcing, the largest generic drug sourcing operation in the United States. The companies started buying generic drugs around the world to sell in U.S. markets.
In March 2015, Cardinal Health signed an agreement to acquire Johnson & Johnson's Cordis (medical) division, a cardiology and endovascular device manufacturer, for $1.94 billion. The acquisition was completed on October 4, 2015. Cardinal sold the division in August 2021 to Hellman & Friedman, a private equity firm, for $1 billion.
In April 2017, Cardinal Health announced the plan to acquire the patient product portfolio from Medtronic for $6.1 billion. The acquisition was completed on July 30, 2017.
In November 2024, Cardinal Health announced the plan to acquire Advanced Diabetes Supply Group (ADSG), a leading national direct-to-patient provider of diabetes medical supplies, for about $1.1 billion with plans to merge the company into its at-Home Solutions business. The at-Home Solutions business includes Edgepark Medical Supplies of Twinsburg, Ohio and United States Medical Supply (US MED) of Doral, Florida. The acquisition was complete by April 2024.
In August 2025, Cardinal Health announced that it would acquire a 75% stake in Solaris Health, the largest urology management services organization (MSO) in the United States, for $1.9 billion in cash.
In July 2026, Cardinal Health agreed to acquire AdaptHealth's diabetes health business and medical-supply provider Strive Medical in separate transactions worth approximately US$360 million in total. The acquisitions were intended to expand its at-Home Solutions business in diabetes and urological care.
Controversy
Role in the Opioid epidemic
Multiple legal settlements have demonstrated Cardinal Health's role in the US Opioid epidemic, though the company never admitted wrongdoing:
December 2016: Cardinal Health settled for $44 million for violations of the Controlled Substances Act brought in allegations from United States Attorneys in districts from Maryland, New York, Florida and Washington.
July 2021: Cardinal Health agreed to pay $6.4 billion to settle thousands of US lawsuits. They were one of four companies to pay $26 billion, including Johnson & Johnson, AmerisourceBergen and McKesson.
May 2022: Settled a derivative suit on behalf of shareholders for $124 million.
August 2024: Settlement with various health plans including insurers and third-party payers for $92.7 million.
August 2024: Settlement with the City of Baltimore for $152.5 million.
Restatements
In September 2004, Cardinal Health announced plans to restate past results for fiscal 2001, 2002, 2003, and the first three quarters of 2004 downward, after an accounting review and an ongoing federal investigation. In 2005, in connection with the Audit Committee's conclusions reached in September and October 2004, the company made certain reclassification and restatement adjustments to its fiscal 2004 and prior historical consolidated financial statements. According to The Wall Street Journal, "Analysts called the restatement decision troubling, yet limited in scope."
FDA action
In August 2006, Cardinal Health ceased production of its Alaris SE infusion pump after approximately 1300 units were seized by the United States Food and Drug Administration (FDA). In February 2007, Cardinal Health signed a consent decree with the FDA which promised procedures to guarantee the safety of the Alaris SE. After FDA inspections, Cardinal Health entered into a further consent agreement with the FDA in 2009.
DEA investigation into Oxycodone diversion
In 2008, Cardinal Health agreed to pay $34 million in civil penalties to settle DEA allegations that it failed to report suspicious orders of hydrocodone. The fine followed a 10-month DEA suspension of a Lakeland, Florida distribution facility and two others in New Jersey and Washington. On February 2, 2012, the Drug Enforcement Administration again suspended the license of the firm's Lakeland distribution center to distribute controlled substances on charges that it had allowed four Florida pharmacies to purchase excessive amounts of controlled substances, in particular oxycodone.
Cardinal Health obtained a restraining order against the suspension, but the suspension was upheld on February 29 by a Federal district court because the court agreed with the DEA that Cardinal Health's activities represented an "imminent danger to the public." The company stated that it blocked two of the pharmacies, (Brooks Pharmacy in Bonita Springs, Florida, and Gulf Coast Medical in Panama City, Florida), and notified the corporate owners of the two pharmacies that were part of national chains, two CVS stores in Sanford, Florida.
In February 2012, Joseph Rannazzisi, chief of the Drug Enforcement Administration’s Office of Diversion Control, issued immediate suspension orders against Cardinal's supply of oxycodone to suspected pill mills. These orders were filed after Deputy Attorney General James M. Cole met with Rannazzisi to ask if he had met with Cardinal about the investigation. Cole stated that he believed “it made good sense to listen to what Cardinal had to say” regarding the investigation. That year, Cardinal and the DEA reached a settlement that suspended Cardinal's facility in Lakeland, Florida from selling pain killers or other drugs for two years. In 2016, Cardinal was fined $44 million for after the investigation concluded.
In January 2022, Cardinal Health, Johnson & Johnson, McKesson, and AmerisourceBergen agreed to pay $26 billion to settle with all but five of the states suing them. Had the states gone to court, the companies could have faced up to $95 billion in penalties.
Finances
Annual financial statistics are displayed below:
Cardinal Health Foundation
The Cardinal Health Foundation is the charitable arm of Cardinal Health. The company makes annual product donations of over $9 million through international relief organizations and provides up to $1,000 in matching funds for every Cardinal Health employee that makes a charitable donation. In 2008, the foundation established its E3 Grant Program. Over the past seven years, the Foundation has invested more than $7.15 million in funding to 241 hospitals, health systems or other health-related organizations.
Cardinal Health also supports organizations such as Ronald McDonald House Charities, and was named Benefactor of the Year at the 2011 Corporate Caring Awards. In 2015, the foundation contributed $3 million to the Solutions for Patient Safety project, which has raised over $11 million nationally for efforts to improve safety initiatives in children's hospitals.
출처: 위키백과 (영어), CC BY-SA 4.0 · 위키백과에서 보기 ↗
CAH 주식 스냅샷 가격, 시가총액, P/E, EPS, ROE, 부채/자본, 52주 범위
CAH 주가 차트 기술 지표가 포함된 일일 OHLCV — 팬, 확대/축소 및 보기 사용자 정의
10년 성과 매출, 순이익, 마진 및 EPS 추세
가치 평가 P/E, P/S, P/B, EV/EBITDA 비율 — 주식이 비싼가요, 싼가요?
수익성 총, 영업 및 순이익률; ROE, ROA, ROIC
재무 건전성 부채, 유동성, 지급능력 — 대차대조표 건전성
성장 매출, EPS 및 순이익 성장률: YoY, 3년 CAGR, 5년 CAGR
자본 효율성 자산 회전율, 재고 회전율, 매출채권 회전율
배당금 배당 수익률, 지급 비율, 배당 이력, 5년 CAGR
| 배당락일 | 금액 |
|---|---|
| 2026년 7월 1일 | $0.5160 |
| 2026년 4월 1일 | $0.5110 |
| 2026년 1월 2일 | $0.5110 |
| 2025년 10월 1일 | $0.5110 |
| 2025년 7월 1일 | $0.5110 |
| 2025년 4월 1일 | $0.5060 |
| 2025년 1월 2일 | $0.5060 |
| 2024년 10월 1일 | $0.5060 |
| 2024년 7월 1일 | $0.5060 |
| 2024년 3월 28일 | $0.5010 |
| 2023년 12월 29일 | $0.5010 |
| 2023년 10월 2일 | $0.5010 |
| 2023년 6월 30일 | $0.5010 |
| 2023년 3월 31일 | $0.4960 |
| 2022년 12월 30일 | $0.4960 |
| 2022년 9월 30일 | $0.4960 |
| 2022년 6월 30일 | $0.4960 |
| 2022년 3월 31일 | $0.4910 |
| 2021년 12월 31일 | $0.4910 |
| 2021년 9월 30일 | $0.4910 |
CAH 분석가 합의 강세 및 약세 애널리스트 의견, 12개월 목표 주가, 상승 여력
- 적극 매수 8 34.8%
- 매수 12 52.2%
- 보유 3 13.0%
- 매도 0 0.0%
- 적극 매도 0 0.0%
12개월 목표 주가
15 명의 애널리스트 · 2026-08-14실적 기록 EPS 실제 vs 예상, 서프라이즈 %, 달성률, 다음 실적 발표일
| 기간 | EPS Actual | EPS 예상 | 서프라이즈 |
|---|---|---|---|
| 2026년 12월 31일 | $2.91 | $2.44 | 0.47% |
| 2026년 6월 30일 | $2.91 | $2.44 | 0.47% |
| 2026년 3월 31일 | $3.17 | $2.82 | 0.35% |
| 2025년 12월 31일 | $2.63 | $2.40 | 0.23% |
| 2025년 9월 30일 | $2.55 | $2.20 | 0.35% |
| 2025년 6월 30일 | $2.08 | $2.06 | 0.02% |
| 2025년 3월 31일 | $2.35 | $2.19 | 0.16% |
동종 기업 비교(GICS 하위 산업) 주요 지표 대 섹터 동종 기업
| 티커 | 시가총액 | P/E | 매출 YoY | 순이익률 | ROE | 매출 총이익률 |
|---|---|---|---|---|---|---|
| CAH | — | 32.9 | 14.2% | 0.67% | -60.5% | 3.8% |
| MCK | $242.30B | 22.5 | 12.4% | 1.2% | -224.3% | 3.6% |
| COR | $60.61B | 39.3 | 9.3% | 0.48% | 144.3% | 3.6% |
| HSIC | $8.81B | 23.3 | 4.0% | 3.0% | 12.0% | 31.1% |
| AHCO | $1.35B | -19.2 | -0.49% | -2.2% | -4.6% | — |
| ACH | — | — | — | — | — | — |
| MEDS | — | — | — | — | — | — |
전체 기본 지표 연도별 모든 지표 — 손익계산서, 대차대조표, 현금흐름
손익계산서 15
| 지표 | 추세 | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $254.25B | $222.58B | $226.83B | $204.98B | $181.33B | $162.47B | $152.92B | $145.53B | $136.81B | $129.98B | $121.55B | $102.53B | |
| Cost of Revenue | $244.47B | $214.41B | $219.41B | $198.10B | $174.84B | $155.69B | $146.05B | $138.70B | $129.63B | $123.43B | $115.00B | $96.82B | |
| Gross Profit | $9.77B | $8.17B | $7.41B | $6.87B | $6.48B | $6.78B | $6.87B | $6.83B | $7.18B | $6.54B | $6.54B | $5.71B | |
| SG&A Expense | $6.13B | $5.38B | $5.00B | $4.80B | $4.51B | $4.53B | $4.57B | $4.48B | $4.60B | $3.77B | $3.65B | $3.24B | |
| Operating Income | $2.61B | $2.27B | $1.24B | $752M | $-607M | $472M | $-4.10B | $2.06B | $126M | $2.12B | $2.46B | $2.16B | |
| Interest Expense | $348M | $215M | $51M | $84M | $147M | $180M | $238M | $294M | $329M | $201M | $178M | $141M | |
| Other Non-op | $31M | $41M | $9M | $-5M | $-22M | $47M | $1M | $-15M | $-23M | $5M | $-5M | $7M | |
| Pretax Income | $2.17B | $2.10B | $1.20B | $663M | $-784M | $323M | $-3.77B | $1.75B | $-228M | $1.92B | $2.28B | $1.97B | |
| Income Tax | $469M | $532M | $348M | $332M | $153M | $-289M | $-79M | $386M | $-487M | $630M | $845M | $755M | |
| Net Income | $1.71B | $1.56B | $852M | $330M | $-938M | $611M | $-3.70B | $1.36B | $256M | $1.29B | $1.43B | $1.22B | |
| EPS (Basic) | $7.27 | $6.48 | $3.48 | $1.27 | $-3.37 | $2.09 | $-12.61 | $4.55 | $0.82 | $4.06 | $4.36 | $3.66 | |
| EPS (Diluted) | $7.23 | $6.45 | $3.45 | $1.26 | $-3.37 | $2.08 | $-12.61 | $4.53 | $0.81 | $4.03 | $4.32 | $3.62 | |
| Shares (Basic) | 236,000,000 | 241,000,000 | 245,000,000 | 261,000,000 | 279,000,000 | 292,000,000 | 293,000,000 | 300,000,000 | 313,000,000 | 317,000,000 | 327,000,000 | 332,000,000 | |
| Shares (Diluted) | 237,000,000 | 242,000,000 | 247,000,000 | 262,000,000 | 279,000,000 | 294,000,000 | 293,000,000 | 301,000,000 | 315,000,000 | 320,000,000 | 330,000,000 | 335,000,000 | |
| EBITDA | $3.57B | $3.06B | $1.95B | $1.42B | $96M | $1.25B | $-3.19B | $3.06B | $1.16B | $2.84B | $3.10B | $2.61B |
대차대조표 25
| 지표 | 추세 | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.86B | $3.87B | $5.13B | $4.08B | $4.72B | $3.41B | $2.77B | $2.53B | $1.76B | $6.88B | $2.36B | $4.62B | |
| Short-term Investments | · | · | $200M | · | · | · | · | · | · | $65M | $113M | $91M | |
| Receivables | $13.81B | $13.24B | $12.08B | $11.11B | $10.56B | $9.10B | $8.26B | $8.45B | $7.80B | $8.05B | $7.41B | $6.52B | |
| Inventory | $17.30B | $16.83B | $14.96B | $16.12B | $15.64B | $14.59B | $13.20B | $12.82B | $12.31B | $11.30B | $10.62B | $9.21B | |
| Other Current Assets | $2.76B | $2.41B | $2.66B | $2.29B | $2.02B | $2.84B | $1.71B | $1.95B | $1.93B | $2.12B | $1.58B | $1.40B | |
| Current Assets | $38.75B | $36.37B | $34.88B | $33.74B | $32.94B | $31.05B | $25.94B | $25.75B | $24.55B | $28.34B | $21.96B | $21.75B | |
| PP&E (Net) | $3.03B | $2.86B | $2.53B | $2.46B | $2.36B | $2.36B | $2.37B | $2.36B | $2.49B | $1.88B | $1.80B | $1.51B | |
| PP&E (Gross) | $7.97B | $7.52B | $6.70B | $6.31B | $5.88B | $5.59B | $5.33B | $5.17B | $5.26B | $4.63B | $4.48B | $4.03B | |
| Accum. Depreciation | $4.93B | $4.66B | $4.17B | $3.85B | $3.52B | $3.23B | $2.96B | $2.81B | $2.77B | $2.75B | $2.68B | $2.53B | |
| Goodwill | $11.44B | $9.69B | $4.72B | $4.61B | $5.86B | $7.99B | $8.36B | $8.38B | $8.32B | $7.22B | $7.17B | $5.07B | |
| Intangibles | $2.19B | $2.49B | $1.73B | $1.47B | $1.77B | $2.10B | $2.92B | $3.43B | $3.91B | $1.99B | $1.99B | $948M | |
| Other Non-current Assets | $1.88B | $1.71B | $1.26B | $1.07B | $953M | $951M | $1.19B | $1.05B | $682M | $681M | $944M | $866M | |
| Total Assets | $57.30B | $53.12B | $45.12B | $43.35B | $43.88B | $44.45B | $40.77B | $40.96B | $39.95B | $40.11B | $34.12B | $30.14B | |
| Accounts Payable | $38.28B | $34.71B | $31.76B | $29.93B | $27.13B | $23.70B | $21.37B | $21.54B | $19.68B | $17.91B | $17.31B | $14.37B | |
| Short-term Debt | · | · | · | · | · | · | · | · | · | $855M | $0 | $0 | |
| Current Liabilities | $43.90B | $38.90B | $35.64B | $33.74B | $30.55B | $27.62B | $23.61B | $24.11B | $22.89B | $21.22B | $19.70B | $17.24B | |
| Capital Leases | $861M | $654M | $400M | $375M | $388M | $374M | $341M | · | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | · | $1.75B | $1.81B | $1.95B | $1.70B | $328M | |
| Total Debt | · | · | · | · | · | · | · | · | · | $855M | $0 | · | |
| Common Stock | $2.89B | $2.96B | $2.92B | $2.75B | $2.81B | $2.81B | $2.79B | $2.76B | $2.73B | $2.70B | $3.01B | $3.00B | |
| Retained Earnings | $2.01B | $783M | $-286M | $-642M | $-280M | $1.21B | $1.17B | $5.43B | $4.64B | $4.97B | $6.42B | $5.52B | |
| Treasury Stock | $7.61B | $6.37B | $5.68B | $4.91B | $3.13B | $2.19B | $2.07B | $1.79B | $1.22B | $731M | $2.76B | $2.25B | |
| AOCI | $-165M | $-155M | $-167M | $-151M | $-114M | $-34M | $-104M | $-79M | $-92M | $-125M | $-116M | $-23M | |
| Stockholders' Equity | $-2.88B | $-2.78B | $-3.21B | $-2.96B | $-709M | $1.79B | $1.79B | $6.33B | $6.06B | $6.81B | $6.55B | $6.26B | |
| Liabilities + Equity | $57.30B | $53.12B | $45.12B | $43.35B | $43.88B | $44.45B | $40.77B | $40.96B | $39.95B | $40.11B | $34.12B | $30.14B |
현금 흐름 19
| 지표 | 추세 | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $956M | $790M | $710M | $692M | $692M | $783M | $913M | $1.00B | $1.03B | $717M | $641M | $451M | |
| Stock-based Comp | $367M | $244M | $121M | $96M | $81M | $89M | $90M | $82M | $85M | $96M | $111M | $110M | |
| Deferred Tax | $91M | $243M | $-104M | $-40M | $14M | $496M | $-961M | $-83M | $-1.01B | $291M | $87M | $219M | |
| Amort. of Intangibles | $361M | $303M | $264M | $281M | $311M | $428M | $512M | $531M | $574M | $395M | $355M | $191M | |
| Restructuring | $106M | $88M | $175M | $95M | $101M | $114M | $122M | $125M | $176M | $56M | $25M | $44M | |
| Other Non-cash | $2.05B | $-441M | $2.18B | $1.82B | $3.27B | $450M | $5.61B | $360M | $2.41B | · | $705M | $545M | |
| Operating Cash Flow | $5.17B | $2.40B | $3.76B | $2.84B | $3.17B | $2.43B | $1.96B | $2.72B | $2.77B | $1.18B | $2.97B | $2.54B | |
| CapEx | $649M | $547M | $511M | $481M | $387M | $400M | $375M | $328M | $384M | $387M | $465M | $300M | |
| Investing Cash Flow | $-2.58B | $-5.59B | $-1.85B | $-454M | $567M | $-378M | $493M | $338M | $-5.61B | $-405M | $-4.08B | $-849M | |
| Debt Issued | $1.00B | $2.90B | $1.14B | · | · | · | · | · | · | · | · | · | |
| Net Debt Issued | $347M | $2.46B | $357M | $-579M | $-885M | $-570M | $-1.40B | $-1.10B | $-954M | $-310M | $-6M | $-1.22B | |
| Stock Repurchased | $1.36B | $765M | $750M | $2.00B | $1.00B | $200M | $350M | $600M | $550M | $600M | $651M | $1.04B | |
| Net Stock Activity | $-1.36B | $-765M | $-750M | $-2.00B | $-1.00B | $-200M | $-350M | $-600M | $-550M | $-600M | $-651M | $-1.04B | |
| Dividends Paid | $491M | $494M | $499M | $525M | $559M | $573M | $569M | $577M | $581M | $577M | $512M | $460M | |
| Financing Cash Flow | $-1.60B | $1.94B | $-847M | $-3.05B | $-2.46B | $-1.32B | $-2.20B | $-2.29B | $-2.28B | $3.75B | $-1.14B | $60M | |
| Net Change in Cash | $982M | $-1.26B | $1.06B | $-669M | $1.36B | $636M | $240M | $768M | $-5.12B | $4.52B | $-2.26B | $1.75B | |
| Taxes Paid | $338M | $444M | $191M | $156M | $-766M | $273M | $368M | $311M | $425M | $686M | $635M | $529M | |
| Free Cash Flow | $4.53B | $1.85B | $3.25B | $2.36B | $2.73B | $2.03B | $1.58B | $2.39B | $2.38B | $797M | $2.51B | $2.24B | |
| Levered FCF | $4.25B | $1.69B | $3.21B | $2.32B | $2.55B | $1.69B | $1.35B | $2.16B | $2.76B | $662M | $2.39B | $2.15B |
수익성 8
| 지표 | 추세 | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 3.8% | 3.7% | 3.3% | 3.4% | 3.6% | 4.2% | 4.5% | 4.7% | 5.2% | 5.0% | 5.4% | 5.6% | |
| Operating Margin | 1.0% | 1.0% | 0.55% | 0.35% | -0.33% | 0.29% | -2.7% | 1.4% | 0.09% | 1.6% | 2.0% | 2.1% | |
| Net Margin | 0.67% | 0.70% | 0.38% | 0.13% | -0.51% | 0.38% | -2.4% | 0.94% | 0.19% | · | 1.2% | 1.2% | |
| Pretax Margin | 0.86% | 0.94% | 0.53% | 0.31% | -0.42% | 0.20% | -2.5% | 1.2% | -0.17% | 1.5% | 1.9% | 1.9% | |
| EBITDA Margin | 1.4% | 1.4% | 0.86% | 0.69% | 0.05% | 0.77% | -2.1% | 2.1% | 0.85% | 2.2% | 2.5% | 2.5% | |
| ROA | 3.1% | 3.2% | 1.9% | 0.60% | -2.1% | 1.4% | -9.0% | 3.4% | 0.64% | · | 4.4% | 4.3% | |
| ROE | -60.5% | -52.1% | -27.6% | -14.7% | -172.5% | 34.1% | -91.1% | 22.0% | 4.0% | · | 22.3% | 19.2% | |
| ROIC | -71.1% | -61.1% | -27.5% | -10.5% | 101.9% | 49.9% | -224.3% | 25.4% | -2.4% | 18.6% | 23.6% | 21.3% |
유동성 및 지급능력 4
| 지표 | 추세 | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.9 | 0.9 | 1.0 | 1.0 | 1.1 | 1.1 | 1.1 | 1.1 | 1.1 | 1.3 | 1.1 | 1.3 | |
| Quick Ratio | 0.4 | 0.4 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.4 | 0.7 | 0.5 | 0.7 | |
| Debt / Equity | · | · | · | · | · | · | · | · | · | 0.1 | 0.0 | · | |
| Interest Coverage | 7.5 | 10.6 | 24.4 | 7.8 | -4.0 | 2.6 | -17.2 | 7.0 | 0.4 | 10.5 | 13.8 | 15.3 |
효율성 3
| 지표 | 추세 | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 4.6 | 4.5 | 5.1 | 4.7 | 4.1 | 3.8 | 3.7 | 3.6 | 3.4 | 3.5 | 3.8 | 3.7 | |
| Inventory Turnover | 14.3 | 13.5 | 14.1 | 12.5 | 11.6 | 11.2 | 11.2 | 11.0 | 11.0 | 11.3 | 11.6 | 11.1 | |
| Receivables Turnover | 18.8 | 17.6 | 19.6 | 18.7 | 18.4 | 18.7 | 18.3 | 17.9 | 17.3 | 16.8 | 17.5 | 17.2 |
성장률 10
| 지표 | 추세 | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 14.2% | -1.9% | 10.7% | 13.0% | 11.6% | 6.2% | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 7.4% | 7.1% | 11.8% | 10.3% | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 9.4% | 7.8% | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 12.1% | 87.0% | 173.8% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | 79.0% | · | 18.4% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | 28.3% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 9.8% | 83.2% | 158.2% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 73.2% | · | 11.7% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | 22.9% | · | · | · | · | · | · | · | · | · | · | · | |
| Dividend CAGR 5Y | -3.0% | -2.8% | · | · | · | · | · | · | · | · | · | · |
가치 평가 (TTM) 6
| 지표 | 추세 | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $254.25B | $222.58B | $226.83B | $204.98B | $181.33B | $162.47B | $152.92B | $145.53B | $136.81B | $129.98B | $121.55B | $102.53B | |
| Net Income TTM | $1.71B | $1.56B | $852M | $330M | $-938M | $611M | $-3.70B | $1.36B | $256M | $1.29B | $1.43B | $1.22B | |
| P/E | 32.9 | 26.0 | 28.5 | 75.1 | -15.5 | 27.4 | -4.1 | 10.4 | 60.3 | 19.3 | 18.1 | 23.1 | |
| Earnings Yield | 3.0% | 3.8% | 3.5% | 1.3% | -6.5% | 3.6% | -24.2% | 9.6% | 1.7% | 5.2% | 5.5% | 4.3% | |
| Payout Ratio | 28.6% | 31.6% | 58.6% | 201.1% | -59.9% | 93.8% | -15.4% | 42.3% | 226.9% | · | 35.9% | 37.9% | |
| Annual Payout | $491M | $494M | $499M | $525M | $559M | $573M | $569M | $577M | $581M | $577M | $512M | $460M |
손익계산서 15
| 지표 | 추세 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $63.67B | $60.94B | $65.63B | $64.01B | $60.16B | $54.88B | $55.26B | $52.28B | $59.87B | $54.87B | $57.44B | $54.65B | $53.42B | $50.50B | $51.47B | $49.59B | |
| Cost of Revenue | $61.11B | $58.44B | $63.23B | $61.69B | $57.96B | $52.76B | $53.32B | $50.38B | $57.98B | $52.93B | $55.59B | $52.91B | $51.61B | $48.69B | $49.78B | $48.00B | |
| Gross Profit | $2.56B | $2.50B | $2.40B | $2.32B | $2.20B | $2.12B | $1.94B | $1.90B | $1.88B | $1.94B | $1.85B | $1.74B | $1.81B | $1.81B | $1.68B | $1.60B | |
| SG&A Expense | $1.62B | $1.54B | $1.50B | $1.46B | $1.48B | $1.31B | $1.31B | $1.28B | $1.28B | $1.27B | $1.27B | $1.19B | $1.23B | $1.17B | $1.18B | $1.20B | |
| Operating Income | $729M | $509M | $707M | $668M | $428M | $730M | $549M | $568M | $401M | $369M | $505M | $-32M | $162M | $604M | $-86M | $123M | |
| Interest Expense | · | · | $88M | $80M | $74M | $74M | $35M | $32M | $9M | $28M | $3M | $11M | $6M | $26M | $24M | $24M | |
| Other Non-op | $26M | $-16M | $11M | $10M | $30M | $9M | $-3M | $5M | $-1M | $1M | $10M | $-1M | $-10M | $-2M | $6M | $-3M | |
| Pretax Income | $554M | $392M | $630M | $598M | $384M | $665M | $511M | $541M | $391M | $342M | $512M | $-44M | $146M | $576M | $-104M | $96M | |
| Income Tax | $154M | $12M | $159M | $144M | $141M | $157M | $110M | $124M | $158M | $80M | $143M | $-33M | $143M | $209M | $-27M | $-3M | |
| Net Income | $398M | $399M | $467M | $450M | $239M | $506M | $400M | $416M | $235M | $261M | $368M | $-12M | $5M | $365M | $-77M | $98M | |
| EPS (Basic) | · | · | · | $1.89 | · | · | · | $1.71 | · | $1.07 | $1.50 | $-0.05 | · | $1.43 | $-0.30 | $0.36 | |
| EPS (Diluted) | · | · | · | $1.88 | · | · | · | $1.70 | · | $1.07 | $1.50 | $-0.05 | · | $1.41 | $-0.30 | $0.36 | |
| Shares (Basic) | -473,000,000 | 235,000,000 | 236,000,000 | 238,000,000 | -484,000,000 | 240,000,000 | 242,000,000 | 243,000,000 | -492,000,000 | 243,000,000 | 245,000,000 | 249,000,000 | -527,000,000 | 256,000,000 | 261,000,000 | 271,000,000 | |
| Shares (Diluted) | -475,000,000 | 236,000,000 | 237,000,000 | 239,000,000 | -487,000,000 | 241,000,000 | 243,000,000 | 245,000,000 | -493,000,000 | 245,000,000 | 246,000,000 | 249,000,000 | -530,000,000 | 258,000,000 | 261,000,000 | 273,000,000 | |
| EBITDA | · | $757M | $941M | $901M | · | $730M | $549M | $750M | · | $367M | $482M | $158M | · | $572M | $-119M | $308M |
대차대조표 21
| 지표 | 추세 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.86B | $3.94B | $2.78B | $4.59B | $3.87B | $3.33B | $3.81B | $2.87B | $5.13B | $3.72B | $4.59B | $3.85B | · | $3.99B | $3.65B | $3.49B | |
| Receivables | $13.81B | $13.65B | $13.66B | $13.77B | $13.24B | $12.67B | $12.37B | $11.78B | $12.08B | $11.57B | $11.79B | $11.27B | · | $10.99B | $11.42B | $11.04B | |
| Inventory | $17.30B | $18.01B | $20.12B | $17.56B | $16.83B | $16.16B | $16.90B | $15.62B | $14.96B | $17.28B | $18.45B | $16.99B | · | $16.62B | $17.26B | $15.89B | |
| Other Current Assets | $2.76B | $2.47B | $2.67B | $2.60B | $2.41B | $2.40B | $2.62B | $2.59B | $2.66B | $3.16B | $2.82B | $2.58B | · | $1.90B | $2.26B | $2.27B | |
| Current Assets | $38.75B | $38.06B | $39.23B | $38.54B | $36.37B | $34.59B | $35.76B | $32.91B | $34.88B | $35.73B | $37.66B | $34.69B | · | $33.50B | $34.60B | $32.70B | |
| PP&E (Net) | $3.03B | $2.93B | $2.88B | $2.83B | $2.86B | $2.66B | $2.56B | $2.54B | $2.53B | $2.47B | $2.45B | $2.44B | · | $2.36B | $2.34B | $2.34B | |
| PP&E (Gross) | $7.97B | · | · | · | $7.52B | · | · | · | $6.70B | · | · | · | · | · | · | · | |
| Accum. Depreciation | $4.93B | · | · | · | $4.66B | · | · | · | $4.17B | · | · | · | · | · | · | · | |
| Goodwill | $11.44B | $11.41B | $11.61B | $9.71B | $9.69B | $8.91B | $5.49B | $4.72B | $4.72B | $4.79B | $4.02B | $4.03B | $4.61B | $5.00B | $4.99B | $5.67B | |
| Intangibles | $2.19B | $2.28B | $2.37B | $2.40B | $2.49B | $2.11B | $1.95B | $1.66B | $1.73B | $1.72B | $1.35B | $1.41B | · | $1.57B | $1.63B | $1.69B | |
| Other Non-current Assets | $1.88B | $2.00B | $2.00B | $1.75B | $1.71B | $1.60B | $1.25B | $1.23B | $1.26B | $1.17B | $1.10B | $1.15B | · | $951M | $927M | $985M | |
| Total Assets | $57.30B | $56.69B | $58.08B | $55.23B | $53.12B | $49.87B | $47.00B | $43.06B | $45.12B | $45.88B | $46.57B | $43.71B | · | $43.38B | $44.48B | $43.39B | |
| Accounts Payable | $38.28B | $37.83B | $39.00B | $36.86B | $34.71B | $32.81B | $31.30B | $30.36B | $31.76B | $32.09B | $34.26B | $31.54B | · | $29.60B | $30.08B | $28.36B | |
| Current Liabilities | $43.90B | $41.99B | $43.31B | $40.27B | $38.90B | $36.66B | $35.22B | $34.68B | $35.64B | $36.31B | $38.29B | $35.06B | · | $32.50B | $33.21B | $31.56B | |
| Capital Leases | $861M | · | · | · | $654M | · | · | · | $400M | · | · | · | · | · | · | · | |
| Common Stock | $2.89B | $2.81B | $2.85B | $2.75B | $2.96B | $2.95B | $2.93B | $2.83B | $2.92B | $2.89B | $2.85B | $2.73B | · | $2.82B | $2.75B | $2.58B | |
| Retained Earnings | $2.01B | $1.73B | $1.46B | $1.12B | $783M | $664M | $283M | $14M | $-286M | $-289M | $-425M | $-654M | · | $-342M | $-560M | $-301M | |
| Treasury Stock | $7.61B | $7.22B | $7.03B | $6.58B | $6.37B | $6.38B | $6.03B | $5.96B | $5.68B | $5.70B | $5.72B | $5.40B | $4.91B | $4.55B | $4.25B | $3.88B | |
| AOCI | $-165M | $-161M | $-153M | $-159M | $-155M | $-176M | $-180M | $-155M | $-167M | $-160M | $-155M | $-165M | · | $-142M | $-146M | $-176M | |
| Stockholders' Equity | $-2.88B | $-2.83B | $-2.88B | $-2.88B | $-2.78B | $-2.95B | $-2.99B | $-3.28B | $-3.21B | $-3.27B | $-3.45B | $-3.49B | · | $-2.22B | $-2.21B | $-1.78B | |
| Liabilities + Equity | $57.30B | $56.69B | $58.08B | $55.23B | $53.12B | $49.87B | $47.00B | $43.06B | $45.12B | $45.88B | $46.57B | $43.71B | · | $43.38B | $44.48B | $43.39B |
현금 흐름 17
| 지표 | 추세 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $241M | $248M | $234M | $233M | $209M | $207M | $192M | $182M | $186M | $177M | $175M | $172M | $176M | $175M | $170M | $171M | |
| Stock-based Comp | $58M | $129M | $87M | $93M | $153M | $31M | $30M | $30M | $33M | $31M | $28M | $29M | $27M | $21M | $25M | $23M | |
| Amort. of Intangibles | $95M | $95M | $84M | $87M | $89M | $77M | $69M | $68M | $73M | $64M | $63M | $64M | $70M | $69M | $71M | $71M | |
| Restructuring | $40M | $25M | $21M | $20M | $27M | $28M | $9M | $24M | $69M | $53M | $28M | $25M | $33M | $16M | $17M | $29M | |
| Other Non-cash | · | · | · | $197M | · | · | · | $-2.27B | · | · | · | $339M | · | · | · | $-281M | |
| Operating Cash Flow | $1.69B | $1.82B | $686M | $973M | $1.52B | $2.92B | $-396M | $-1.65B | $2.08B | $-54M | $1.16B | $528M | $863M | $1.36B | $597M | $23M | |
| CapEx | $264M | $146M | $131M | $108M | $232M | $126M | $99M | $90M | $193M | $112M | $114M | $92M | $217M | $109M | $85M | $70M | |
| Investing Cash Flow | $-281M | $-181M | $-1.98B | $-142M | $-1.63B | $-2.90B | $-976M | $-88M | $166M | $-1.85B | $-105M | $-63M | $-206M | $-91M | $-87M | $-70M | |
| Debt Issued | $0 | $0 | $0 | $1.00B | $0 | $0 | · | · | $0 | · | · | · | · | · | · | · | |
| Net Debt Issued | · | · | · | $488M | · | · | · | $-9M | · | · | · | $-7M | · | · | · | $-7M | |
| Stock Repurchased | $350M | $250M | $383M | $375M | $0 | $375M | $15M | $375M | $0 | $0 | $250M | $500M | $500M | $250M | $250M | $1.00B | |
| Net Stock Activity | · | · | · | $-375M | · | · | · | $-375M | · | · | · | $-500M | · | · | · | $-1.00B | |
| Dividends Paid | $120M | $120M | $122M | $129M | $120M | $124M | $122M | $128M | $122M | $122M | $124M | $131M | $126M | $128M | $129M | $142M | |
| Financing Cash Flow | $-490M | $-483M | $-519M | $-110M | $663M | $-507M | $2.33B | $-540M | $-859M | $1.03B | $-353M | $-666M | $-592M | $-934M | $-362M | $-1.16B | |
| Net Change in Cash | $919M | $1.16B | $-1.82B | $719M | $548M | $-484M | $943M | $-2.27B | $1.39B | $-878M | $710M | $-206M | $58M | $336M | $162M | $-1.23B | |
| Free Cash Flow | · | · | · | $865M | · | · | · | $-1.74B | · | · | · | $453M | · | · | · | $-47M | |
| Levered FCF | · | · | · | $804M | · | · | · | $-1.76B | · | · | · | $456M | · | · | · | $-72M |
수익성 8
| 지표 | 추세 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | · | 4.1% | 3.6% | 3.6% | · | 3.9% | 3.5% | 3.6% | · | 3.5% | 3.2% | 3.2% | · | 3.5% | 3.2% | 3.2% | |
| Operating Margin | · | 0.84% | 1.1% | 1.0% | · | 1.3% | 0.99% | 1.1% | · | 0.67% | 0.84% | -0.03% | · | 1.1% | -0.23% | 0.28% | |
| Net Margin | · | 0.65% | 0.71% | 0.70% | · | 0.92% | 0.72% | 0.80% | · | 0.47% | 0.61% | 0.01% | · | 0.68% | -0.25% | 0.22% | |
| Pretax Margin | · | 0.64% | 0.96% | 0.93% | · | 1.2% | 0.92% | 1.0% | · | 0.62% | 0.85% | -0.05% | · | 1.1% | -0.27% | 0.22% | |
| EBITDA Margin | · | 1.2% | 1.4% | 1.4% | · | 1.3% | 0.99% | 1.4% | · | 0.67% | 0.84% | 0.29% | · | 1.1% | -0.23% | 0.62% | |
| ROA | · | 0.75% | 0.89% | 0.92% | · | 1.1% | 0.85% | 0.96% | · | 0.58% | 0.78% | 0.01% | · | 0.81% | -0.29% | 0.25% | |
| ROE | · | -13.8% | -15.9% | -14.6% | · | -16.3% | -12.4% | -12.3% | · | -9.4% | -12.5% | -0.19% | · | -23.6% | 21.4% | -56.7% | |
| ROIC | · | -17.4% | -18.3% | -17.6% | · | -18.9% | -14.4% | -13.4% | · | -8.5% | -10.1% | -0.09% | · | -16.4% | 5.1% | -7.8% |
유동성 및 지급능력 3
| 지표 | 추세 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | · | 0.9 | 0.9 | 1.0 | · | 0.9 | 1.0 | 0.9 | · | 1.0 | 1.0 | 1.0 | · | 1.0 | 1.0 | 1.0 | |
| Quick Ratio | · | 0.4 | 0.4 | 0.5 | · | 0.4 | 0.5 | 0.4 | · | 0.4 | 0.4 | 0.4 | · | 0.5 | 0.5 | 0.5 | |
| Interest Coverage | · | · | 8.0 | 8.3 | · | 9.9 | 15.7 | 17.8 | · | 11.1 | 60.2 | -1.0 | · | 20.4 | -4.8 | 5.5 |
효율성 3
| 지표 | 추세 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | 1.1 | 1.2 | 1.3 | · | 1.1 | 1.2 | 1.2 | · | 1.2 | 1.3 | 1.3 | · | 1.2 | 1.2 | 1.1 | |
| Inventory Turnover | · | 3.4 | 3.4 | 3.7 | · | 3.2 | 3.0 | 3.1 | · | 3.1 | 3.1 | 3.2 | · | 3.0 | 3.1 | 3.1 | |
| Receivables Turnover | · | 4.6 | 5.0 | 5.0 | · | 4.5 | 4.6 | 4.5 | · | 4.9 | 5.0 | 4.9 | · | 4.8 | 4.9 | 4.9 |
가치 평가 (TTM) 5
| 지표 | 추세 | Q4 2026 | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | · | $245.45B | $239.78B | $226.43B | · | $217.29B | $219.85B | $219.24B | · | $217.46B | $214.06B | $206.21B | · | $196.39B | $191.35B | $183.85B | |
| Net Income TTM | · | $1.82B | $1.82B | $1.77B | · | $1.58B | $1.45B | $1.03B | · | $982M | $644M | $374M | · | $-1.00B | $-1.32B | $-973M | |
| P/E | · | · | · | · | · | 32.6 | 28.0 | 26.2 | · | 28.5 | 39.4 | 61.1 | · | · | · | · | |
| Earnings Yield | · | · | · | · | · | 3.1% | 3.6% | 3.8% | · | 3.5% | 2.5% | 1.6% | · | · | · | · | |
| Payout Ratio | · | · | · | 28.7% | · | · | · | 30.8% | · | · | · | 2620.0% | · | · | · | 129.1% |
재무제표 손익계산서, 대차대조표, 현금흐름 — 연간, 지난 5년
손익계산서
| 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | |
|---|---|---|---|---|---|
| 매출 | $254.25B | $222.58B | $226.83B | $204.98B | $181.33B |
| 매출 총이익률 % | 3.8% | 3.7% | 3.3% | 3.4% | 3.6% |
| 영업이익률 % | 1.0% | 1.0% | 0.55% | 0.35% | -0.33% |
| 순이익 | $1.71B | $1.56B | $852M | $330M | $-938M |
| 희석 EPS | $7.23 | $6.45 | $3.45 | $1.26 | $-3.37 |
대차대조표
| 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | |
|---|---|---|---|---|---|
| 유동비율 | 0.9 | 0.9 | 1.0 | 1.0 | 1.1 |
| 당좌 비율 | 0.4 | 0.4 | 0.5 | 0.5 | 0.5 |
현금 흐름
| 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | |
|---|---|---|---|---|---|
| 잉여현금흐름 | $4.53B | $1.85B | $3.25B | $2.36B | $2.73B |
최신 뉴스 이 회사 관련 최근 헤드라인
나의 지표 나만의 관심 목록 — 전체 기본 재무제표에서 선택한 항목
중요한 지표를 선택하세요 — 위 전체 기본 재무제표의 아무 행 옆에 있는 ➕를 클릭하세요.
선택 항목이 저장되어 모든 티커에서 유지됩니다.
기관 투자자 (13F) 1,618개의 제출자 · $31.0B 전체 · 기준일 2026년 6월 30일
분기별 SEC 양식 13F에서 이 주식을 보유하고 있다고 보고하는 기관. 롱 포지션만 해당하며, 단일 제출자는 별도의 옵션 레그에 대해 두 번 나타날 수 있습니다. 대규모 상쇄 풋/콜 포지션은 일반적으로 방향성에 대한 확신보다는 시장 조성 또는 헤지된 재고를 반영합니다.
| 신규 포지션 | 청산 포지션 | 증가함 | 감소 | 순주식 변동 |
|---|---|---|---|---|
| 162 (-12 이전 분기 대비) | 80 (-20 이전 분기 대비) | 516 (-30 이전 분기 대비) | 545 (+38 이전 분기 대비) | +35.4M |
Q1 2026 대비 비교. SEC 양식 13F 제출은 분기 말로부터 45일 이내에 마감되며, 지연 제출자를 위한 짧은 유예 기간이 추가됩니다. 해당 기간 내에 있는 분기는 가장 최근에 완전히 보고된 쌍을 선호하여 건너뜁니다.
| 기관 | 가치 | 주식 | % 추적된 13F 중 | 유형 |
|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $3,632,811,706 | 15,292,186 | 11.74% | 주식 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $3,258,822,899 | 13,717,894 | 10.53% | 주식 |
| WELLINGTON MANAGEMENT GROUP LLP | $3,254,296,668 | 13,698,841 | 10.51% | 주식 |
| STATE STREET CORP | $2,842,909,265 | 11,967,121 | 9.18% | 주식 |
| GEODE CAPITAL MANAGEMENT, LLC | $1,350,305,229 | 5,709,017 | 4.36% | 주식 |
| WCM INVESTMENT MANAGEMENT, LLC | $971,445,537 | 4,112,461 | 3.14% | 주식 |
| NORGES BANK | $885,248,810 | 3,726,422 | 2.86% | 주식 |
| BNP PARIBAS FINANCIAL MARKETS | $499,624,076 | 2,103,149 | 1.61% | 주식 |
| VICTORY CAPITAL MANAGEMENT INC | $469,793,667 | 1,977,579 | 1.52% | 주식 |
| VANGUARD FIDUCIARY TRUST CO | $315,702,986 | 1,328,940 | 1.02% | 주식 |
| VANGUARD GROUP INC | $277,003,725 | 1,347,950 | 0.89% | 주식 |
| Robeco Institutional Asset Management B.V. | $258,918,781 | 1,089,909 | 0.84% | 주식 |
| DIMENSIONAL FUND ADVISORS LP | $244,584,818 | 1,029,571 | 0.79% | 주식 |
| ENVESTNET ASSET MANAGEMENT INC | $230,523,823 | 970,390 | 0.74% | 주식 |
| BlackRock, Inc. | $225,912,433 | 950,970 | 0.73% | 주식 |
| Man Group plc | $220,862,620 | 929,713 | 0.71% | 주식 |
| FMR LLC | $211,855,495 | 891,798 | 0.68% | 주식 |
| GOLDMAN SACHS GROUP INC | $199,229,035 | 838,647 | 0.64% | 주식 |
| ProShare Advisors LLC | $197,187,154 | 830,052 | 0.64% | 주식 |
| NORDEA INVESTMENT MANAGEMENT AB | $192,568,890 | 809,283 | 0.62% | 주식 |
| Legal & General Group Plc | $184,918,605 | 778,408 | 0.60% | 주식 |
| JANE STREET GROUP, LLC | $169,712,864 | 714,400 | 0.55% | 콜 옵션 |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $160,043,538 | 677,519 | 0.52% | 주식 |
| Swiss National Bank | $157,644,816 | 663,600 | 0.51% | 주식 |
| JANE STREET GROUP, LLC | $153,701,320 | 647,000 | 0.50% | 풋 옵션 |
| Mitsubishi UFJ Asset Management Co., Ltd. | $141,722,832 | 596,577 | 0.46% | 주식 |
| 1832 Asset Management L.P. | $139,039,117 | 585,280 | 0.45% | 주식 |
| Sumitomo Mitsui Trust Group, Inc. | $132,703,867 | 558,612 | 0.43% | 주식 |
| RENAISSANCE TECHNOLOGIES LLC | $130,681,756 | 550,100 | 0.42% | 주식 |
| BANK OF AMERICA CORP /DE/ | $126,454,568 | 532,306 | 0.41% | 주식 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $123,081,499 | 518,107 | 0.40% | 주식 |
| Vanguard Global Advisers, LLC | $122,136,010 | 514,127 | 0.39% | 주식 |
| LPL Financial LLC | $120,559,117 | 507,489 | 0.39% | 주식 |
| RHUMBLINE ADVISERS | $116,899,342 | 492,084 | 0.38% | 주식 |
| UBS Group AG | $116,739,360 | 491,410 | 0.38% | 주식 |
| National Pension Service | $113,432,762 | 477,491 | 0.37% | 주식 |
| FRED ALGER MANAGEMENT, LLC | $111,665,316 | 470,051 | 0.36% | 주식 |
| SEI INVESTMENTS CO | $110,593,700 | 465,540 | 0.36% | 주식 |
| VANGUARD ASSET MANAGEMENT, Ltd | $109,533,215 | 461,076 | 0.35% | 주식 |
| BARCLAYS PLC | $108,067,946 | 454,908 | 0.35% | 주식 |
| LAZARD ASSET MANAGEMENT LLC | $106,528,318 | 448,427 | 0.34% | 주식 |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | $104,481,026 | 439,809 | 0.34% | 주식 |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | $104,081,450 | 438,127 | 0.34% | 주식 |
| California Public Employees Retirement System | $103,583,999 | 436,033 | 0.33% | 주식 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $101,984,508 | 429,300 | 0.33% | 콜 옵션 |
| TWO SIGMA ADVISERS, LP | $96,441,150 | 469,300 | 0.31% | 주식 |
| JANUS HENDERSON GROUP PLC | $96,030,102 | 454,526 | 0.31% | 주식 |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $95,040,000 | 400,069 | 0.31% | 주식 |
| SILVERCREST ASSET MANAGEMENT GROUP LLC | $94,526,074 | 397,904 | 0.31% | 주식 |
| ING GROEP NV | $90,805,885 | 382,244 | 0.29% | 주식 |
| Retirement Systems of Alabama | $89,453,931 | 376,553 | 0.29% | 주식 |
| BANK OF NOVA SCOTIA | $88,870,008 | 374,095 | 0.29% | 주식 |
| RAYMOND JAMES FINANCIAL INC | $88,654,749 | 373,189 | 0.29% | 주식 |
| Artemis Investment Management LLP | $87,745,162 | 369,360 | 0.28% | 주식 |
| TD Asset Management Inc | $85,393,555 | 359,461 | 0.28% | 주식 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $85,236,528 | 358,800 | 0.28% | 풋 옵션 |
| Delta Accumulation, LLC | $81,886,932 | 344,700 | 0.26% | 풋 옵션 |
| STOREBRAND ASSET MANAGEMENT AS | $80,500,769 | 338,865 | 0.26% | 주식 |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $79,269,258 | 333,681 | 0.26% | 주식 |
| ROYAL BANK OF CANADA | $79,026,000 | 332,656 | 0.26% | 주식 |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $78,334,941 | 370,711 | 0.25% | 주식 |
| Ensign Peak Advisors, Inc | $78,327,333 | 329,716 | 0.25% | 주식 |
| GFS Advisors, LLC | $76,777,103 | 55 | 0.25% | 주식 |
| Integral Health Asset Management, LLC | $71,268,000 | 300,000 | 0.23% | 주식 |
| Focus Partners Wealth | $69,563,786 | 292,826 | 0.22% | 주식 |
| ZACKS INVESTMENT MANAGEMENT | $69,526,717 | 292,669 | 0.22% | 주식 |
| PRUDENTIAL FINANCIAL INC | $69,141,838 | 291,050 | 0.22% | 주식 |
| FIRST TRUST ADVISORS LP | $63,253,014 | 266,262 | 0.20% | 주식 |
| Caisse de depot et placement du Quebec | $63,072,655 | 265,502 | 0.20% | 주식 |
| MILLENNIUM MANAGEMENT LLC | $60,514,609 | 254,734 | 0.20% | 주식 |
| CANADA PENSION PLAN INVESTMENT BOARD | $60,313,158 | 253,886 | 0.19% | 주식 |
| Gotham Asset Management, LLC | $59,744,915 | 251,494 | 0.19% | 주식 |
| NATIXIS | $57,996,711 | 244,135 | 0.19% | 주식 |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $57,683,884 | 243,678 | 0.19% | 주식 |
| AMERIPRISE FINANCIAL INC | $56,823,880 | 239,198 | 0.18% | 주식 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $56,038,504 | 235,892 | 0.18% | 주식 |
| ALLIANCEBERNSTEIN L.P. | $55,998,840 | 265,008 | 0.18% | 주식 |
| Vest Financial, LLC | $55,494,016 | 233,600 | 0.18% | 주식 |
| AVIVA PLC | $54,653,054 | 230,060 | 0.18% | 주식 |
| COOKSON PEIRCE & CO INC | $54,112,422 | 227,784 | 0.17% | 주식 |
| APG Asset Management N.V. | $52,132,088 | 250,895 | 0.17% | 주식 |
| Delta Accumulation, LLC | $50,101,404 | 210,900 | 0.16% | 콜 옵션 |
| Quantinno Capital Management LP | $49,716,731 | 209,280 | 0.16% | 주식 |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $48,954,227 | 206,071 | 0.16% | 주식 |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $48,870,606 | 205,719 | 0.16% | 주식 |
| Zurich Insurance Group Ltd/FI | $47,315,063 | 199,171 | 0.15% | 주식 |
| CRAWFORD INVESTMENT COUNSEL INC | $45,812,739 | 192,847 | 0.15% | 주식 |
| Cetera Investment Advisers | $45,437,576 | 191,268 | 0.15% | 주식 |
| Empyrean Capital Partners, LP | $43,758,552 | 184,200 | 0.14% | 주식 |
| Squarepoint Ops LLC | $43,560,427 | 183,366 | 0.14% | 주식 |
| PFA Pension, Forsikringsaktieselskab | $43,480,161 | 183,028 | 0.14% | 주식 |
| Davidson Kempner Capital Management LP | $43,260,389 | 182,103 | 0.14% | 주식 |
| TEACHER RETIREMENT SYSTEM OF TEXAS | $42,795,484 | 180,146 | 0.14% | 주식 |
| Pictet Asset Management Holding SA | $42,685,837 | 179,688 | 0.14% | 주식 |
| OSAIC HOLDINGS, INC. | $41,443,725 | 174,339 | 0.13% | 주식 |
| CHURCHILL MANAGEMENT Corp | $40,806,561 | 242,896 | 0.13% | 주식 |
| JONES FINANCIAL COMPANIES LLLP | $40,701,876 | 171,074 | 0.13% | 주식 |
| AMF Tjanstepension AB | $40,543,890 | 170,668 | 0.13% | 주식 |
| Voleon Capital Management LP | $40,128,160 | 168,918 | 0.13% | 주식 |
| CITADEL ADVISORS LLC | $40,028,860 | 168,500 | 0.13% | 콜 옵션 |
회사 내부자 85 명의 내부자 · 45 임원 · 37 이사
| 내부자 | 역할 | 마지막 활동 | 보유 주식 수 | 매수 12개월 | 매도 12개월 | 순매수/매도 12개월 |
|---|---|---|---|---|---|---|
| Deborah Weitzman | CEO, PSS Segment | 2026년 8월 15일 F | 85,255 | 0 | 1 | $-3,216,375 |
| Stephen M Mason | CEO, GMPD Segment | 2026년 8월 15일 F | 53,061 | 0 | 3 | $-6,187,063 |
| Jason M. Hollar | Chief Executive Officer | 2026년 8월 15일 F | 315,132 | 0 | 5 | $-21,424,216 |
| Michael C Kaufmann | CEO | 2022년 8월 15일 M | 601,065 | 0 | 0 | $0 |
| Victor L. Crawford | CEO, Pharmaceutical Segment | 2022년 8월 15일 F | 105,699 | 0 | 0 | $0 |
| Jon L Giacomin | CEO, Medical Segment | 2019년 8월 15일 F | 61,387 | 0 | 0 | $0 |
| Donald M Casey Jr. | CEO, Medical Segment | 2017년 9월 15일 F | 146,503 | 0 | 0 | $0 |
| Michael A Lynch | CEO, Medical Segment | 2012년 2월 27일 M | 89,204 | 0 | 0 | $0 |
| Kerry R Clark | Former Chairman and CEO | 2009년 9월 1일 A | 238,635 | 0 | 0 | $0 |
| Mark W Parrish | CEO - HSCS | 2007년 9월 2일 F | 68,041 | 0 | 0 | $0 |
| Ronald K Labrum | CEO-Supply Chain Svcs. | 2006년 5월 16일 M | 36,082 | 0 | 0 | $0 |
| Joseph C Papa | Chmn & CEO, Pharm Techn & Svcs | 2004년 12월 13일 A | 14,400 | 0 | 0 | $0 |
| Aaron E Alt | Chief Financial Officer | 2026년 8월 15일 F | 62,495 | 0 | 2 | $-7,177,390 |
| Jorge M Gomez | Chief Financial Officer | 2018년 11월 8일 F | 39,582 | 0 | 0 | $0 |
| Jeffrey William Henderson | Chief Financial Officer | 2014년 8월 27일 M | 67,190 | 0 | 0 | $0 |
| Richard J Miller | EVP & CFO | 2003년 11월 17일 A | — | 0 | 0 | $0 |
| George L Fotiades | President & COO | 2003년 1월 15일 P | 80,278 | 0 | 0 | $0 |
| Valerie Christine Pitteroff | Chief Human Resources Officer | 2026년 8월 15일 F | 11,757 | 0 | 0 | $0 |
| Mary C. Scherer | Chief Accounting Officer | 2026년 8월 15일 F | 5,113 | 0 | 1 | $-1,009,826 |
| Michelle D. Greene | Chief Information Officer | 2026년 8월 15일 F | 21,980 | 0 | 2 | $-2,009,043 |
| Jessica L Mayer | Chief Legal/Compliance Officer | 2026년 8월 15일 F | 62,512 | 0 | 3 | $-5,666,833 |
| Ola M Snow | Chief Human Resources Officer | 2025년 8월 19일 S | 15,431 | 0 | 2 | $-4,192,917 |
| Patricia M English | Chief Accounting Officer | 2022년 8월 15일 F | 9,000 | 0 | 0 | $0 |
| Brian S Rice | Chief Information Officer | 2022년 8월 15일 F | 37,850 | 0 | 0 | $0 |
| Michele Holcomb | EVP - Strategy & Corp. Dev. | 2022년 8월 15일 F | 44,491 | 0 | 0 | $0 |
| Stuart G Laws | SVP & Chief Accounting Officer | 2020년 8월 15일 F | 12,289 | 0 | 0 | $0 |
| Craig S Morford | Chief Legal/Compliance Officer | 2018년 12월 3일 F | 126,301 | 0 | 0 | $0 |
| Patricia Morrison | Chief Information Officer | 2018년 8월 31일 F | 30,725 | 0 | 0 | $0 |
| Pamela O. Kimmet | Chief Human Resources Officer | 2018년 8월 15일 F | 22,612 | 0 | 0 | $0 |
| George S Barrett | Executive Chairman | 2018년 8월 15일 F | 502,630 | 0 | 0 | $0 |
| Carole S Watkins | Chief HR Officer | 2016년 5월 20일 M | 31,585 | 0 | 0 | $0 |
| Falk T Stephen | EVP, Gen. Counsel & Corp. Sec. | 2015년 11월 30일 G | 32,455 | 0 | 0 | $0 |
| Meghan Fitzgerald | EVP, Strategy & Health Policy | 2015년 11월 17일 F | 16,760 | 0 | 0 | $0 |
| Mark R Blake | EVP - Strategy & Corp. Dev. | 2014년 11월 7일 M | 20,409 | 0 | 0 | $0 |
| Ivan K Fong | CLO & Secretary | 2008년 11월 1일 F | 50,886 | 0 | 0 | $0 |
| Vivek Jain | EVP - Corp. Dev. & Strategy | 2008년 9월 26일 A | 39,594 | 0 | 0 | $0 |
| Daniel J Walsh | EVP, Chf Ethcs & Compl Offcr | 2007년 11월 26일 I | 1,740 | 0 | 0 | $0 |
| Eric Slusser | EVP, CAO & Controller | 2007년 6월 4일 M | 8,573 | 0 | 0 | $0 |
| Brendan A Ford | EVP-Corporate Development | 2006년 9월 2일 F | 85,978 | 0 | 0 | $0 |
| RUCCI ANTHONY J | EVP & Chief Admin. Officer | 2005년 9월 6일 G | 55,382 | 0 | 0 | $0 |
| Gary D Dolch | EVP - Quality & Reg. Affairs | 2005년 9월 2일 A | 6,137 | 0 | 0 | $0 |
| Jody R Davids | EVP & CIO | 2005년 9월 2일 A | 4,607 | 0 | 0 | $0 |
| Paul S Williams | EVP, CLO & Secretary | 2005년 2월 17일 G | 7,000 | 0 | 0 | $0 |
| Gary S Jensen | SVP - Corporate Controller | 2004년 8월 23일 A | 2,462 | 0 | 0 | $0 |
| Stephen S Thomas | EVP-Group Pres.-AIS | 2004년 2월 24일 M | 31,039 | 0 | 0 | $0 |
| Hall Patricia Hemingway | 이사 | 2026년 4월 15일 A | 28,645 | 0 | 0 | $0 |
| Christine Mundkur | 이사 | 2025년 11월 5일 A | 7,536 | 0 | 0 | $0 |
| Gregory B Kenny | 이사 | 2025년 11월 5일 A | 64,194 | 0 | 0 | $0 |
| Sudhakar Ramakrishna | 이사 | 2025년 3월 15일 A | 1,049 | 0 | 0 | $0 |
| Michelle Brennan | 이사 | 2024년 11월 6일 A | 7,019 | 0 | 0 | $0 |
SEC 양식 3/4/5 제출 서류 기준 내부자; 순매수/매도는 공개 시장 거래만 해당
행동주의자 및 5% 이상 소유자 3 보유
SEC 서류 13D를 제출한 투자자 — 발행인에 영향을 미치려는 의도로 5% 이상의 실질 소유권(행동주의 지분, 이사회 캠페인, M&A). 각 행은 해당 제출자의 포지션에 대한 가장 최근에 알려진 상태를 보여줍니다.
| 제출자 | 제출됨 | 지분 | 상태 | 목적 | 제출 |
|---|---|---|---|---|---|
| Cardinal Health, Inc. ×2 제출 서류 | 2014년 6월 5일 | — | 최초 제출 | — | SEC |
| 미공개 보고자 | 2004년 7월 2일 | — | 최초 제출 | — | SEC |
| 미공개 보고자 | 2004년 5월 28일 | — | 최초 제출 | M&A / 매각 | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF 보유 현황 224 ETF 보유
가중치는 직접적인 주식 보유(N-PORT)만 반영합니다. 레버리지 또는 파생 상품 기반 펀드는 표시되지 않은 추가 스왑 노출을 보유할 수 있습니다.
| 펀드 | 비중 | 단위 | 기준일 | 출처 |
|---|---|---|---|---|
| EGGS · Tidal Trust III | 4.07% | 11,627 NS | 2026년 5월 31일 | N-PORT |
| BCUS · Exchange Listed Funds Trust | 2.96% | 16,250 NS | 2026년 5월 31일 | N-PORT |
| IYK · iShares Trust | 2.53% | 151,717 SH | 2026년 8월 8일 | 일간 |
| POWA · Invesco Exchange-Traded Self-Indexe… | 2.21% | 17,153 SH | 2026년 8월 8일 | 일간 |
| FXH · First Trust Exchange-Traded AlphaDE… | 1.98% | 89,549 NS | 2026년 4월 30일 | N-PORT |
| NUMV · Nushares ETF Trust | 1.83% | 40,961 NS | 2026년 4월 30일 | N-PORT |
| FLOW · Global X Funds | 1.70% | 2,476 NS | 2026년 5월 31일 | N-PORT |
| ZECP · Zacks Trust | 1.69% | 29,490 NS | 2026년 5월 31일 | N-PORT |
| RSPH · Invesco Exchange-Traded Fund Trust | 1.66% | 54,825 SH | 2026년 8월 8일 | 일간 |
| COWZ · Pacer Funds Trust | 1.62% | 1,528,597 NS | 2026년 4월 30일 | N-PORT |
| QQWZ · Pacer Funds Trust | 1.62% | 3,926 NS | 2026년 4월 30일 | N-PORT |
| PWV · Invesco Exchange-Traded Fund Trust | 1.56% | 118,283 SH | 2026년 8월 8일 | 일간 |
| NOBL · ProShares Trust | 1.41% | 791,661 NS | 2026년 5월 31일 | N-PORT |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 1.38% | 796 NS | 2026년 4월 30일 | N-PORT |
| KNG · First Trust Exchange-Traded Fund IV | 1.37% | 239,259 NS | 2026년 4월 30일 | N-PORT |
| VFMV · VANGUARD WELLINGTON FUND | 1.34% | 23,570 SH | 2026년 8월 8일 | 일간 |
| RWL · Invesco Exchange-Traded Fund Trust … | 1.34% | 563,995 SH | 2026년 8월 8일 | 일간 |
| GROZ · Zacks Trust | 1.19% | 5,456 NS | 2026년 5월 31일 | N-PORT |
| SRHQ · Elevation Series Trust | 1.09% | 10,932 NS | 2026년 4월 30일 | N-PORT |
| SPVM · Invesco Exchange-Traded Fund Trust | 1.08% | 5,969 SH | 2026년 8월 8일 | 일간 |
| RPV · Invesco Exchange-Traded Fund Trust | 1.08% | 77,480 SH | 2026년 8월 8일 | 일간 |
| ESMV · iShares Trust | 1.06% | 350 SH | 2026년 8월 8일 | 일간 |
| NULV · Nushares ETF Trust | 1.03% | 110,401 NS | 2026년 4월 30일 | N-PORT |
| AMOM · Exchange Listed Funds Trust | 1.00% | 1,584 NS | 2026년 4월 30일 | N-PORT |
| VOE · VANGUARD INDEX FUNDS | 0.96% | 1,504,470 SH | 2026년 8월 8일 | 일간 |
| VHT · VANGUARD WORLD FUND | 0.82% | 707,389 SH | 2026년 8월 8일 | 일간 |
| ABFL · Abacus FCF ETF Trust | 0.80% | 20,613 NS | 2026년 4월 30일 | N-PORT |
| ROE · EA Series Trust | 0.79% | 10,387 NS | 2026년 5월 29일 | N-PORT |
| VAMO · Cambria ETF Trust | 0.78% | 3,359 NS | 2026년 4월 30일 | N-PORT |
| AVIE · AMERICAN CENTURY ETF TRUST | 0.74% | 387 NS | 2026년 5월 31일 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0.74% | 109,528 NS | 2026년 4월 30일 | N-PORT |
| UPSD · ETF Series Solutions | 0.73% | 3,833 NS | 2026년 4월 30일 | N-PORT |
| IWP · iShares Trust | 0.73% | 619,589 SH | 2026년 8월 8일 | 일간 |
| IXJ · iShares Trust | 0.70% | 122,846 SH | 2026년 8월 8일 | 일간 |
| LGDX · Tidal Trust III | 0.69% | 4,947 NS | 2026년 4월 30일 | N-PORT |
| RXL · ProShares Trust | 0.67% | 2,454 NS | 2026년 5월 31일 | N-PORT |
| LSEQ · Harbor ETF Trust | 0.66% | 524 NS | 2026년 4월 30일 | N-PORT |
| CURE · Direxion Shares ETF Trust | 0.65% | 4,692 NS | 2026년 4월 30일 | N-PORT |
| FTC · First Trust Exchange-Traded AlphaDE… | 0.58% | 38,214 NS | 2026년 4월 30일 | N-PORT |
| QARP · DBX ETF Trust | 0.58% | 2,209 NS | 2026년 5월 29일 | N-PORT |
| CLSE · Trust for Professional Managers | 0.58% | 18,083 NS | 2026년 5월 31일 | N-PORT |
| FLCV · Federated Hermes ETF Trust | 0.56% | 2,763 NS | 2026년 5월 31일 | N-PORT |
| VO · VANGUARD INDEX FUNDS | 0.54% | 5,075,476 SH | 2026년 8월 8일 | 일간 |
| QUVU · Hartford Funds Exchange-Traded Trust | 0.52% | 4,667 NS | 2026년 4월 30일 | N-PORT |
| ITAN · EA Series Trust | 0.50% | 2,246 NS | 2026년 5월 29일 | N-PORT |
| EVUS · iShares Trust | 0.49% | 7,746 SH | 2026년 8월 8일 | 일간 |
| KRMA · Global X Funds | 0.47% | 2,880 NS | 2026년 5월 31일 | N-PORT |
| IUS · Invesco Exchange-Traded Self-Indexe… | 0.47% | 18,983 SH | 2026년 8월 8일 | 일간 |
| JMID · Janus Detroit Street Trust | 0.45% | 423 NS | 2026년 4월 30일 | N-PORT |
| SFGV · EA Series Trust | 0.42% | 24,321 NS | 2026년 5월 29일 | N-PORT |